Anti-EGFL7 antibody [EPR22603-113]
- KO Validated
- BOND RX™ Validated
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(4 Publications)
Rabbit Recombinant Monoclonal EGFL7 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples. Cited in 4 publications.
View Alternative Names
MEGF7, UNQ187/PRO1449, EGFL7, Epidermal growth factor-like protein 7, EGF-like protein 7, Multiple epidermal growth factor-like domains protein 7, NOTCH4-like protein, Vascular endothelial statin, Zneu1, Multiple EGF-like domains protein 7, VE-statin
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-EGFL7 antibody [EPR22603-113] (AB256451)
Immunohistochemical analysis of paraffin-embedded human placenta tissue labeling EGFL7 with ab256451 at 1/500 dilution (1.12 ug/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on human placenta (PMID : 24751645) is observed. The section was incubated with ab256451 for 30 mins at RT. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-EGFL7 antibody [EPR22603-113] (AB256451)
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HUVEC (Human umbilical vein endothelial cell) cells labeling EGFL7 with ab256451 at 1/50, (10 μg/ml), followed by ab150077 AlexaFluor®488 Goat anti-Rabbit secondary antibody at 1/1000 dilution (Green). Confocal image showing cytoplasmic staining in HUVEC cells. Negative control : Jurkat (PMID : 15162510). ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) was used to counterstain tubulin at 1/200 dilution (Red). The nuclear counterstain was DAPI (Blue).
Secondary antibody only control : Secondary antibody is ab150077 AlexaFluor®488 Goat anti-Rabbit secondary at 1/1000 dilution.
- IHC-P
Unknown
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-EGFL7 antibody [EPR22603-113] (AB256451)
Immunohistochemical analysis of paraffin-embedded human pancreas tissue labeling EGFL7 with ab256451 at 1/500 dilution (1.12 ug/ml) followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101). Positive staining on blood vessels in human pancreas (PMID : 18497746) is observed. The section was incubated with ab256451 for 30 mins at RT. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.
Secondary antibody only control : Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (ab209101).
- WB
Lab
Western blot - Anti-EGFL7 antibody [EPR22603-113] (AB256451)
Western blot : Anti-EGFL7 antibody [EPR22603-113] ab256451 staining at 1/1000 dilution, shown in green; Mouse anti alpha Tubulin ab7291 loading control staining at 1/20000 dilution, shown in magenta. A band was observed at 30 kDa. To generate this image, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3pc Milk in TBS-0.1 % Tween 20 (TBS-T) before incubation with primary antibodies overnight at 4 C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit 800CW and Goat anti-Mouse 680RD at 1/20,000 dilution.
All lanes:
Western blot - Anti-EGFL7 antibody [EPR22603-113] (ab256451) at 1/1000 dilution
Lane 1:
Wild-type A549 BFA (5g/mL,6h) at 20 µg
Lane 2:
Wild-type A549 BFA (0 g/mL,6h) at 20 µg
Lane 3:
EGFL7 knockout A549 BFA (5 g/mL, 6 h) at 20 µg
Lane 4:
EGFL7 knockout A549 BFA (0 g/mL, 6 h) at 20 µg
Lane 5:
HUVEC at 20 µg
Lane 6:
Jurkat at 20 µg
Secondary
All lanes:
Goat anti-Rabbit 800CW & Goat anti-Mouse 680RD at 1/20000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa
false
- WB
Lab
Western blot - Anti-EGFL7 antibody [EPR22603-113] (AB256451)
The molecular weight observed is consistent with what has been described in the literature (PMID : 18497746).
Negative control : Jurkat (PMID : 15162510).
Exposure time : 3 minutes.
Blocking and Diluting Buffer and concentration : 5% NFDM/TBST.
All lanes:
Western blot - Anti-EGFL7 antibody [EPR22603-113] (ab256451) at 1/1000 dilution
Lane 1:
Human placenta lysate at 20 µg
Lane 2:
HUVEC (human umbilical vein endothelial cell) whole cell lysate at 20 µg
Lane 3:
Jurkat (human t cell leukemia t lymphocyte) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa
false
Related conjugates and formulations (1)
-
Anti-EGFL7 antibody [EPR22603-113] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
EGFL7 plays an essential role in blood vessel development and maintenance. It is involved in the modulation of endothelial cell behavior primarily through cell proliferation migration and organization. EGFL7 influences angiogenesis by affecting the extracellular matrix environment but it does not form part of a larger protein complex. It serves as a regulator by interacting directly with other components of the angiogenic process.
Pathways
Research has established EGFL7 as a significant participant in the angiogenesis and Notch signaling pathways. It interacts closely with proteins such as COX-2 within the angiogenic pathway and through its efficacy impacts the downstream signaling events in vessels' formation and repair. The proper functioning of these pathways highlights the importance of EGFL7 in vascular biology.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (4)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in oncology 14:1440906 PubMed39346724
2024
Applications
Unspecified application
Species
Unspecified reactive species
Biomedicines 12: PubMed39200393
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of oncology 2022:7498771 PubMed36072982
2022
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 23: PubMed35008490
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com